DACOPLICE® Home

Clinical Information

Support & Services

Dacoplice dosing and therapy management
Learn more
Review safety data
Review Safety data
Efficacy
Review efficacy data

References:

  1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466.
  2. Mok TS, Cheng Y, Zhou X, et al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021;81(2):257-266.
  3. Local Prescribing Document for DACOPLICE®. LPD Version 4. Pfizer India_LPDDAC042021.

Please click on Prescribing Information link to view safety and adverse events information of DACOPLICE®

PP-DAC-IND-0093 22-07-2021